Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients? Didier ConcordetPeggy GandiaPierre-Louis Toutain Current Opinion Open access 04 April 2019 Pages: 827 - 833
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors Maddalena CentanniDirk Jan A. R. MoesJ. G. Coen van Hasselt Review Article Open access 28 February 2019 Pages: 835 - 857
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab Kioa Lente WijnsmaRob ter HeineRoger J. Brüggemann Review Article Open access 13 February 2019 Pages: 859 - 874
Interactions Between Antiepileptic and Antibiotic Drugs: A Systematic Review and Meta-Analysis with Dosing Implications Carla CarnovaleMarco PozziSonia Radice Systematic Review 07 November 2018 Pages: 875 - 886
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children Elizabeth J. ThompsonHuali WuMichael Cohen-Wolkowiez Original Research Article 06 March 2019 Pages: 887 - 898
The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children’s Oncology Group Ryan J. BeechinorPatrick A. ThompsonDaniel Gonzalez Original Research Article 27 February 2019 Pages: 899 - 910
Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort Jeffry AdiwidjajaAlan V. BoddyAndrew J. McLachlan Original Research article 24 January 2019 Pages: 911 - 926
Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults Guo-Fu LiQing-Shan ZhengHartmut Derendorf Original Research Article 15 February 2019 Pages: 927 - 941
Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma Li YanBing WangLorin K. Roskos Original Research Article Open access 11 March 2019 Pages: 943 - 958
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Patrick Nicolas Letter to the Editor 03 June 2019 Pages: 959 - 960
Authors’ Reply to Nicolas: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 03 June 2019 Pages: 961 - 963
Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Joël CosteXavier BertagnaMahmoud Zureik Letter to the Editor 03 June 2019 Pages: 965 - 966
Authors’ Reply to Coste et al.: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 03 June 2019 Pages: 967 - 968
Comment on “Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients?” Alain MunafoAxel Krebs-BrownClaire Castello-Bridoux Letter to the Editor Open access 12 June 2019 Pages: 969 - 971
Authors’ Reply to Castello-Bridoux et al.: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor Open access 12 June 2019 Pages: 973 - 975
Comment on: Levothyrox® New and Old Formulations: Are They Switchable for Millions of Patients? Philippe Tréchot Letter to the Editor 12 June 2019 Pages: 977 - 978
Author’s Reply to Trechot: “Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?” Didier ConcordetPeggy GandiaPierre-Louis Toutain Letter to the Editor 12 June 2019 Pages: 979 - 980
Comment on “Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients” Iris K. MinichmayrMarkus Zeitlinger Letter to the Editor 02 May 2019 Pages: 981 - 982
